In the world's major economies, while also exploring the road to recovery, an increase of nearly 20% of the annual production value,digital thermometer gross profit increased by more than 40% of the biopharmaceutical industry in Beijing, but the ambitious brewing over how to achieve development.
In the October 25 -27, held its fourteenth session of the Beijing International Forum on the biomedical industry, biomedical industry how to make Beijing the city's goal of world missions based in the existing industrial base to achieve leapfrog development, clinical thermometer the Beijing into a global pharmaceutical innovation city, into the biomedical industry giants from around the common issues.
Industrial base shape.
Data show that Beijing biomedical industry in 2009 totaled 39.42 billion yuan industrial output value,ear thermometer up 16.2%; total profit as high as 66.6 billion yuan, up 49.3%; margin reached 17.2%, ranking first in the country.
2009 Beijing biomedical industry enterprises the main business income of 49 billion yuan,digital blood pressure monitor accounting for the city's main business income of bio-pharmaceutical industry, 75% and 80% of total profits. Bayer, Beijing Novartis, General Electric Medical Hangwei three main business income of foreign pharmaceutical industrial enterprises in Beijing ranks the top three. A number of key enterprises have the opportunity to come to the fore, the Beijing based bio-pharmaceutical industry strength.
High-quality foreign investment into bio-pharmaceutical industry growth driving Beijing's powerful engine. In recent years, Beijing Foreign Capital Beijing enterprises accounted for the proportion of the pharmaceutical industry increased year by year. In 2009, foreign investment in the pharmaceutical industry in Beijing and Hong Kong, Macao-invested enterprises in the main business income and total profits of the pharmaceutical industry accounted for 52% of the city and 54%.
Experts in Beijing gathered a large number of bio-pharmaceutical industry development potential of key enterprises, attracting Bayer, Sanofi-Aventis, Tong Ren Tang Group, amendments and other domestic and foreign pharmaceutical giants, contains a tremendous leaps and bounds energy, entirely possible in the "second five" strategic industries during the move from the pillar industries.
Fired the starting gun leaps and bounds.
April 23 this year, with the Beijing development projects across the biomedical industry (G20 works) start, Beijing started the development of bio-pharmaceutical industry across the starting gun. Joint Science and Technology Commission People's Bank of Beijing Business Management and Banking Bureau jointly issued the "Beijing to promote the development of bio-pharmaceutical industry across the financial incentive pilot program," took the lead in the implementation of pilot bio-pharmaceutical industry, financial incentives, subsidies to special funds through the establishment of risk, to support financial institutions to increase credit support for bio-pharmaceutical companies.
Since the launch of G20 works in the city Science and Technology Commission, City Commission by letter, Zhongguancun Administrative Committee, Municipal Investment Promotion Bureau and other relevant government agencies to promote collaboration, through "a product of a policy, a business a policy," the implementation of such measures, and achieved number of gratifying achievements.
January to July this year, 23 companies completed the first sale of G20 11.09 billion, a profit of 2.27 billion, accounting for sales of Beijing Pharmaceutical Industry 44.1%, 54.9% of profits will be of bio-pharmaceutical industry development in Beijing the main force. Ted Pharmaceuticals, Sanofi-Aventis, Music & Poor health care, double Heron Pharmaceutical, biotechnology and other G20 hundred companies Thailand increased more than 30% year on year to become an important carrier of industrialization across.
G20 project led a group of 1 billion yuan heavy varieties projects under construction. Sanofi-Aventis of France invest 90 million U.S. dollars building the latest generation of the world (third generation) long-acting insulin, "more time" project started in the Beijing Economic and Technological Development Zone; Beijing from Hebei Yiling Pharmaceutical million headquarters to transfer Variety "Shensongyangxin Capsule" and "Lianhuaqingwen particles" officially put into operation in Beijing; Yangtze Huang Haiyan Su cough medicine project is also about to put into capsules.
Works to promote the G20, a group of "foundry" landing in Beijing, optimizing the industrial environment. Oda international production of biological macromolecules, "foundry", TCL core components of medical equipment "foundry" to the international pharmaceutical solid preparation Ridge "foundry" and green gold of natural plant extracts can be multi-functional foundry smooth construction of four platforms, as the construction industry an important part of the environment.
Across the route to development.
Participation in international division of labor, Beijing witnessed the strength of bio-pharmaceutical companies, but also across the enterprise to realize its growth path development; compliance with international standards, participating in international cooperation must cross the threshold. In the "one world, unified" concept under the guidance of China's biotechnology R & D Services Alliance (ABO Union) international breakthrough with the standards, eight units of time passed ISO9001: 2008 quality management system certification, the five agencies certified by the AAALAC , 3 institutions for the U.S. FDA's GLP GLP inspection, an organization meet the WHO standards by cGMP certification, became standards in the biomedical field the most leading international standards CRO organization. Only the first half of this year, ABO Union to take orders 18 794, the sales income 490 million yuan, of which up to 170 million yuan of overseas orders and with Amgen, Roche, Novartis, AstraZeneca and other famous international enterprises to establish stable cooperation relationship.
Beijing to further promote the internationalization of biomedical industry pace to achieve the grand goal of developing by leaps and bounds, ABO Alliance Worldwide Partner Conference at its fourteenth session of the Beijing International Forum in the biomedical industry successfully held, focusing on "enhancing international capabilities to participate in international innovation cooperation "theme, inviting the United States PPD, Roche, the United States and other internationally renowned biomedical Quintiles business executives for multinational companies in China CRO CRO selection and promotion of innovative drugs in China and other aspects of international in-depth discussions to explore a domestic pharmaceutical enterprises and multinational pharmaceutical companies of cooperation.
Return to the cradle of entrepreneurship.
Biomedical industry to achieve leapfrog development Beijing, the Beijing municipal government will biomedical industry base in the Daxing basis, to create "the development of China's biomedical industry across the main front, the Beijing Urban Construction landmark world," the "trough of China", and further create Beijing bio-pharmaceutical industry environment, to attract talented people to join the company's presence at home and abroad.
According to reports, "Chinese Medicine Valley" will work to improve the soft environment for industrial development, integration of all resources to build a professional platform for the introduction of intermediaries, intermediary organizations, to build a specialized industrial chain, providing intellectual property protection, finance, accounting, legal and associated with the medical professional GMP, GSP certification and other services to form suitable for the development of bio-pharmaceutical industry environment, entrepreneurship, investment and financing, life, property, etc. for the students provide a series of preferential policies and support, attract, identify, cultivate a group of leading international technology, industrial potential, the field of national key projects to support high-quality students to start businesses and become entrepreneurs overseas to return home cradle.
Currently, "Chinese Medicine Valley" construction plan has been launched. Fourteenth session of the Beijing International Forum on the development of bio-pharmaceutical industry, experts said that in the R & D services and technology transfer as pharmaceutical giant focus of today, Beijing to seize the opportunity to become a global influence with the city medical innovation, the global pharmaceutical giant should better use of Beijing "China's trough," the platform, reduce production and research and development to achieve cost targets while speeding up the pace of medical innovation.
The city is becoming a global pharmaceutical innovation in Beijing, not only contributed to the global pattern of change in the acceleration of the pharmaceutical industry, and to help Beijing build a new emergency response system for infectious diseases quickly, greatly reducing the damage and loss of outbreaks of infectious diseases. According to reports, hand, foot and mouth disease in recent years raging, ABO Union member-owned technology, based on the EV71 virus, rapid diagnostic reagents and vaccine development as the starting point, technical resources and pathogens through the integration and sharing of resources , risk sharing, etc., to complete the relevant disease pathogen detection and vaccine development work, building a capital of sudden onset of acute infectious disease pathogen detection and vaccine development, emergency prevention system, effective support for the city safe.
The current global pattern of transfer of biological industry today, to become a global city of Beijing medical innovation, adhering to the important mission of building a world city, in the G20 project, driven by strong, is bound to Beijing's interpretation of bio-pharmaceutical industry in full swing.